A. Allen

457 total citations
11 papers, 164 citations indexed

About

A. Allen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, A. Allen has authored 11 papers receiving a total of 164 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 5 papers in Genetics. Recurrent topics in A. Allen's work include PARP inhibition in cancer therapy (7 papers), BRCA gene mutations in cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). A. Allen is often cited by papers focused on PARP inhibition in cancer therapy (7 papers), BRCA gene mutations in cancer (5 papers) and Lung Cancer Treatments and Mutations (4 papers). A. Allen collaborates with scholars based in United States, United Kingdom and France. A. Allen's co-authors include Susan M. Domchek, Elżbieta Senkus, Mark E. Robson, Anne Armstrong, Suzette Delaloge, Norikazu Masuda, Nadine Tung, Seock‐Ah Im, Binghe Xu and Pierfranco Conté and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

A. Allen

10 papers receiving 161 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
A. Allen United States	7	138	87	62	50	32	11	164
Alan Barnicle United Kingdom	8	136 1.0×	101 1.2×	76 1.2×	43 0.9×	64 2.0×	19	212
Adrien Buisson France	6	94 0.7×	34 0.4×	73 1.2×	56 1.1×	38 1.2×	16	151
Rinat Yerushalmi Israel	7	139 1.0×	67 0.8×	50 0.8×	19 0.4×	47 1.5×	11	182
JL Blum United States	8	181 1.3×	53 0.6×	47 0.8×	33 0.7×	80 2.5×	25	202
Kathleen Klein Oros Canada	6	63 0.5×	59 0.7×	111 1.8×	67 1.3×	67 2.1×	8	195
Tereza Vaclová Spain	8	61 0.4×	57 0.7×	132 2.1×	74 1.5×	40 1.3×	12	205
Lillian M. Smyth United States	7	92 0.7×	46 0.5×	39 0.6×	34 0.7×	62 1.9×	24	166
Mingchao Xie United States	9	103 0.7×	53 0.6×	65 1.0×	24 0.5×	28 0.9×	14	165
Ruth M. O'Regan United States	3	100 0.7×	40 0.5×	35 0.6×	29 0.6×	92 2.9×	4	158
Fedor V. Moiseyenko Russia	8	77 0.6×	58 0.7×	52 0.8×	18 0.4×	44 1.4×	17	126

Countries citing papers authored by A. Allen

Since Specialization

Citations

This map shows the geographic impact of A. Allen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Allen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Allen more than expected).

Fields of papers citing papers by A. Allen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Allen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Allen. The network helps show where A. Allen may publish in the future.

Co-authorship network of co-authors of A. Allen

This figure shows the co-authorship network connecting the top 25 collaborators of A. Allen. A scholar is included among the top collaborators of A. Allen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Allen. A. Allen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2023). OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European Journal of Cancer. 184. 39–47. 54 indexed citations

Allen, A., et al.. (2022). 116P Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT). Annals of Oncology. 33. S86–S86. 2 indexed citations

Mooradian, Meghan J., et al.. (2021). 100P SPOTLIGHT real-world study: Patient characteristics and treatment patterns in patients with unresectable stage III NSCLC receiving durvalumab after chemoradiotherapy (CRT). Annals of Oncology. 32. S1417–S1418.

Hodgson, Darren, Zhongwu Lai, Simon Dearden, et al.. (2021). Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD. Annals of Oncology. 32(12). 1582–1589. 26 indexed citations

Smit, Hans J.M., Anne Sibille, Fiona McDonald, et al.. (2021). 1171MO PACIFIC-R real-world study: Treatment duration and interim analysis of progression-free survival in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Annals of Oncology. 32. S939–S940. 15 indexed citations

McDonald, Fiona, F. Mornex, Marina Chiara Garassino, et al.. (2021). 79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy. Journal of Thoracic Oncology. 16(4). S738–S739. 10 indexed citations

Thiery-Vuillemin, Antoine, Johann S. de Bono, Fred Saad, et al.. (2020). Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound.. Journal of Clinical Oncology. 38(15_suppl). 5539–5539. 4 indexed citations

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2020). Abstract PD4-03: OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Cancer Research. 80(4_Supplement). PD4–3. 7 indexed citations

Bono, Johann S. de, Karim Fizazi, Fred Saad, et al.. (2019). Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. Annals of Oncology. 30. v328–v329. 32 indexed citations

10.

Penson, Richard T., JA Ledermann, Christopher Brown, et al.. (2017). Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21). Annals of Oncology. 28. v331–v331. 4 indexed citations

11.

Oza, Amit M., Pierre Combe, Jonathan A. Ledermann, et al.. (2017). Evaluation of tumour responses and olaparib efficacy in platinum-sensitive relapsed ovarian cancer (PSROC) patients (pts) with or without measurable disease in the SOLO2 trial (ENGOT Ov-21). Annals of Oncology. 28. v344–v344. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact